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Despite advances in therapy, ovarian cancer remains the most lethal gynecological
malignancy and prognosis has not substantially improved over the past 3 decades.
Immunotherapy is a promising new treatment option. However, the immunosuppressive
cancer microenvironment must be overcome for immunotherapy to be successful.
Here, we present a unique case of spontaneous regression of ovarian carcinoma after
septic peritonitis. A 79-year-old woman was diagnosed with stage IIIc ovarian cancer.
The omental cake biopsy was complicated by sepsis. Although the patient recovered,
her physical condition did not allow further treatment for her ovarian cancer. After 6
months, spontaneous regression of the tumor was observed during surgery. Analysis
of the immune infiltrate in the tissues showed a shift from a pro-tumorigenic to an
anti-tumorigenic immune response after sepsis. Strong activation of the immune system
during sepsis overruled the immunosuppressive tumor microenvironment and allowed for
a potent anti-tumor immune response. More understanding of immunological responses
in cases with cancer and septic peritonitis might be crucial to identify potential new
targets for immunotherapy.
Keywords: regression of ovarian carcinoma, septic peritonitis, immune suppressive tumor environment, anti-
tumor immune response, immunotherapy
HIGHLIGHTS
- Ovarian cancer escapes the immune system by inducing an immunosuppressive tumor
microenvironment.
- Sepsis can induce a potent anti-tumor immune response in ovarian cancer.
- The immune system can induce ovarian cancer regression.
INTRODUCTION
Ovarian cancer is the most lethal gynecological malignancy. Standard of care for epithelial
ovarian cancer patients includes surgical resection and chemotherapy with non-specific cytotoxic
drugs. Despite advances in treatment strategies, such as more aggressive surgery, combination
chemotherapy, intraperitoneal chemotherapy, hyperthermia and targeted molecular therapy, the
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5-year survival rate and quality of life of ovarian cancer patients
has not substantially improved over the past 30 years. Therefore,
new therapeutic approaches are needed. Immunotherapy and
immune modulation are promising treatment options. However,
the immunosuppressive ovarian cancer microenvironment must
be overcome for successful immunotherapy (1, 2).
We hereby present a unique case of spontaneous regression of
a histologically confirmed FIGO stage IIIC serous papillary
ovarian carcinoma after a septic peritonitis. The rare
phenomenon of spontaneous regression and recovery of
cancer after sepsis has been described in several cancer types
over the past centuries, including embryonal and breast cancer,
renal adenocarcinoma, neuroblastoma, melanoma, and sarcoma
or carcinoma of the urinary bladder, but not in ovarian cancer
(3). The mechanisms for spontaneous regression of cancer are
not clear but the remissions are often associated with concurrent
bacterial, fungal, viral or protozoan infections. The most
commonly reported symptom wherein spontaneous regression is
registered is an acute febrile state that is evoked by either natural
or induced acute infection (4).
Septic peritonitis includes inflammation of the peritoneum
that can be caused by microorganisms. It is a life-threatening
condition that requires hospitalization, resuscitation and close
monitoring to prevent systemic spread, which might lead to
organ failure. The strong activation of the immune response
within the peritoneal cavity during sepsis involves both the
innate and adaptive immune system. The host inflammatory
response consequent to initial exposure to pathogens is often
followed by anti-inflammatory forces and these responses are
immunologically highly complex and not completely understood
(5–7). Information on septic peritonitis and spontaneous
regression of ovarian cancer is even more scarce. More
understanding of immunological responses in cases with cancer
and septic peritonitis might be crucial to identify potential new
targets for immunotherapy in the future.
CASE
A 79-year-old woman with an increasingly distended abdomen,
fatigue and dyspnoea was referred to a secondary clinic in
the Netherlands. During primary workup with CT-scan, an
enlarged ovary and extensive ascites with omental cake were
demonstrated. In addition, the serum marker CA-125 was
elevated (808 kU/L). Based on histopathological results of
an omental biopsy and prior aspiration of ascitic fluid the
diagnosis of stage IIIC epithelial ovarian cancer was established.
Unfortunately, the biopsy was complicated by a septic peritonitis
with fever up to 39.8◦C for which she was admitted to the
intensive care unit and was treated accordingly. Differential
diagnosis involved intra-abdominal contamination or bowel
puncture/injury during the biopsy procedure. Although the
patient recovered, her physical condition afterwards did not allow
a surgical debulking procedure or neoadjuvant chemotherapy.
She was discharged from the hospital with palliative comfort care.
Six months later, she was referred to our hospital for a
second opinion as she was in a good physical and mental
condition. During physical examination she did not show signs
of lymphadenopathy, ascites or an abdominal mass. The serum
marker CA-125 was normal (10 E/mL). An additional CT-scan
demonstrated no pulmonary or pleural abnormalities and no
signs of lymphadenopathy. Both the left ovary (42 × 24mm)
and the right ovary (23 × 11mm) were slightly enlarged. There
were no signs of free fluid, ascites, omental cake, peritonitis
carcinomatosis, or other abnormalities.
An uncomplicated laparoscopic bilateral salpingo-
oophorectomy was performed including peritoneal biopsies
and a partial omentectomy along with free fluid collection
from the pouch of Douglas. Intraoperative findings showed an
enlarged left ovary, without further residual tumor deposits
intra-abdominally. In concordance with the prior omental
biopsy, a high-grade serous carcinoma was noted within the left
ovary. There were no tumor deposits detected in the right ovary,
the omentum or in any of the other biopsies. After counseling,
the patient opted for expectant management and did not receive
adjuvant systemic chemotherapy. To date, 42 months after
diagnosis, she shows no signs of recurrent or progressive disease
with a serum CA-125 at 11.0 E/mL.
We conclude that this patient represents a very rare case, and
the only case described in literature, of spontaneous regression
of a histologically confirmed stage IIIC ovarian carcinoma after a
septic peritonitis. Since we were interested in the immunological
mechanisms at play in our patient, we set out to study this further.
MATERIALS AND METHODS
Institutional and Ethical Approval
This study was carried out in accordance with the
recommendation of the “Code of conduct for responsible
use of human tissue,” established by the Federa (Federation of
Dutch Medical Scientific Societies). The study was officially
deemed exempt from medical ethical approval. A signed consent
form was obtained from the patient described in this case
report. Anonymous rest material was used as control tissue. The
experiments were carried out in accordance with the guidelines
and regulations of the Radboudumc. Criteria for ovarian cancer
regression were based on clinical data, such as normalization
of CA-125 serum levels, normal physical examination, no
abnormalities on imaging (ultrasound/CT/MRI) and tumor-free
biopsies evaluated by a pathologist.
Multiplex Immunohistochemistry
Multiplex immunohistochemistry was performed using
sequential staining cycles as described elsewhere (8). In
brief, tissue sections of 4µmwere cut form FFPE tissue. Sections
were deparaffinized in xylene, rehydrated and washed in tap
water. Sections were stained with a T cell panel and macrophage
panel. T cell panel: CD3 (RM-9107, Thermo Fisher), CD8
(M7103, Dako), Foxp3 (14-4777, eBioscience Affymetrix).
Macrophage panel: CD68 (M087601, Dako), CD163 (CD163-
L-CE, Leica). Both panels contained CKAE1/AE3 (ab86734,
Abcam) to visualize tumor cells. Heat mediated antigen retrieval
was performed in citrate. Protein block was performed with TBS-
Tween containing 1% BSA. Primary antibodies were incubated
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for 1 h at room temperature. Sections were incubated with
BrightVision poly-HRP-anti-MS/Rb/Rt IgG (DPVO999HRP,
ImmunoLogic) for 30min, followed by visualization with the
Opal color IHC kit (NEL801001KT), (PerkinElmer). A second
antigen retrieval step with citrate or Tris-EDTAwas performed to
remove the antibody-TSA complex and to continue with the next
staining cycle. Tissue sections were counterstained with DAPI
and mounted in Fluoromount-G (0100-01; SouthernBiotech).
Imaging and Analysis
Tissue slides were imaged with the PerkinElmer Vectra system
(Vectra 3.0.3, Perkin Elmer). InForm software (Version 2.2.1,
PerkinElmer) was used for image analysis. Spectral libraries
were built from single stains and used to unmix multispectral
images.
RESULTS
Multiplex immunohistochemistry was used to visualize the
tumor-infiltrating lymphocytes (CD3, CD8, Foxp3) (9) and
macrophages (CD68, CD163) (10) and to quantify the infiltrating
immune cells in the omental cake biopsy taken before sepsis
and in the carcinoma resected 6 month after sepsis. Untreated
primary tumors from stage III and IV high-grade serous ovarian
cancer patients that did not suffer from sepsis were used as
a control. Sections were stained using an automated-imaging
system and the cell ratios were calculated. The biopsy (before
sepsis) was highly infiltrated by effector CD8+ T cells, as
well as Foxp3+ regulatory T cells (TRegs) (Figures 1A,B). In
contrast, the number of infiltrating TRegs was decreased in
the carcinoma (after sepsis). Overall, there was a shift in the
CD8/TReg ratio (Figure 1C), which was accompanied by a
decrease in the Foxp3 staining intensity (Figure 1D). Before the
sepsis, the ratio was comparable to the mean of the control
tumors. After the sepsis, the CD8/TReg ratio increased, indicating
that the carcinoma contained relatively more effector CD8+ T
cells compared to TRegs. The biopsy and carcinoma were also
stained for macrophage markers. Macrophages can acquire a M1
(CD68+CD163−) or M2 (CD68−/+CD163+) phenotype, having
anti- or pro-tumorigenic effects, respectively (11). Whereas the
biopsy contained high numbers of M1 and M2 macrophages, the
presence of M2macrophages was markedly decreased after sepsis
in the carcinoma (Figures 1A,B). Before sepsis the M1/M2 ratio
was at the lower end of the spectrum of control tumors, whereas
after the sepsis it was higher than the ratio of control tumors
(Figure 1C). The staining intensity for CD163+M2macrophages
was decreased after the sepsis (Figure 1D). These results point
toward a decrease of immunosuppressive cells in the tumor
microenvironment after sepsis.
DISCUSSION
More than 60–80% of ovarian cancer patients are diagnosed
at an advanced stage due to the lack of symptoms and
adequate screening methods. The 5-year survival rates in stage
III and IV ovarian cancer are ∼35 and ∼15%, respectively.
Ovarian cancer is an intra-peritoneal disease, which tends not
to metastasize outside the peritoneal cavity. Current treatment
for advanced disease consists of cytoreductive surgery combined
with chemotherapy. Despite the good initial response to primary
therapy around 70–85% of the patients with advanced stage of
disease develop recurrence and eventually die.
Research has shown that the immune system plays an
important role in ovarian cancer progression and is able
to influence clinical outcome. Activation of the immune
system requires presentation of antigen by antigen-presenting
cells (APCs) to T cells. The cytotoxic effects are driven by
a combination of T-lymphocyte activity, antibody-dependent
mechanisms, and natural killer (NK) cell activation. Most tumors
are in some way recognized by the immune system as tumor
infiltrating lymphocytes (TILs) have been observed within and
around the tumor tissue in a variety of different cancers. In
ovarian cancer, a high number of TILs in the tumor are associated
with a favorable clinical outcome (1).
However, ovarian cancer can escape the immune system via
various mechanisms: (1) evasion of immune recognition; (2)
secretion of immune suppressive factors; and (3) recruitment of
immune suppressive cells (1, 12). TRegs and M2 macrophages in
the ovarian cancer microenvironment are able to inhibit the anti-
tumor immune response of cytotoxic T cells, either by secretion
of immunosuppressive cytokines like IL-10 and TGF-β or via
a cell-cell contact-dependent mechanism (12). Accumulation of
Tregs at the tumor site is associated with reduced survival of
ovarian cancer patients (1). Immunotherapy needs to overcome
the immunosuppressive tumor microenvironment to evoke an
effective anti-tumor immune response.
Different immunotherapeutic strategies can be used to boost
the anti-tumor immune response, including vaccination with
tumor-specific dendritic cells, adoptive T cell therapy and
immune checkpoint blockade (13–16). Several clinical trials
are currently investigating the safety and feasibility of these
approaches in ovarian cancer. Two phase 1 studies showed
that DC vaccination (using whole-tumor lysate) alone or in
combination with bevacizumab or cyclophosphamide was safe,
well tolerable and effective in eliciting a broad anti-tumor
immune response in patients with recurrent ovarian, fallopian
tube or peritoneal cancer (17, 18). Immunotherapy using
ex-vivo expanded tumor-infiltrating lymphocytes or genetically
engineered T cells also demonstrated feasibility and safety in
platinum-resistant or recurrent ovarian cancer with manageable
toxicities (19–21).
The inhibition of immune checkpoints has shown great
success in the treatment of melanoma patients and, therefore,
data on ovarian cancer are eagerly awaited. Antibodies against
CTLA-4 (ipilumumab), PD-1 (nivolumab, pembrolizumab), and
PD-L1 (avelumab, durvalumab) are currently tested in clinical
trials and seem to be well tolerated by ovarian cancer patients
(22, 23). For example, a phase II study for nivolumab in
patients with platinum-resistant ovarian cancer showed partial
response and stable disease in 20 and 25% of the patients,
respectively. Their overall disease control rate in 20 patients
was 45% with grade 3 or 4 treatment-related adverse events
occurring in eight (40%) patients (24). Others showed that
pembrolizumab and avelumab in phase 1 clinical trials were
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FIGURE 1 | Multiplex IHC on tissue before and after sepsis. (A) Images showing T cell infiltration and macrophage infiltration in tissue before (omentum biopsy) and
after (tumor resection) sepsis. CKAE1/AE3 was used to visualize tumor cells. Effector T cells were characterized as CD3+CD8+, regulatory T cells as CD3+Foxp3+,
M1 macrophages as CD68+, and M2 macrophages as CD163+. (B) CD8T cells, TRegs, M1 and M2 macrophages per mm
2. Immune cells were quantified in control
tissue, and in tissue obtained before and after sepsis. (C) CD8 effector T cell/TReg ratio and M1/M2 ratio before and after sepsis. (D) Average staining intensity of
immune cell markers before and after sepsis. Unstained tissue was used as control. Untreated primary tumor from stage III and IV ovarian cancer patient were used as
control (n = 16). Red line indicates mean.
very well tolerated, with an acceptable safety profile and with
durable antitumor activity in patients with advanced ovarian,
fallopian tube or peritoneal cancer. Regarding treatment-
related adverse events after treatment with pembrolizumab,
73.1% of the patients had grade 1–2 adverse events with
only one grade 3 adverse event (23). For avelumab, grade
3 or 4 treatment-related adverse events occurred in 10.2%
(25–27). Currently there are two other phase 2 clinical trials
underway to determine the safety, feasibility and efficacy of
durvalumab (anti-PD-L1) and ipilimumab (anti-CTLA-4) in
first-line neo-adjuvant setting for ovarian cancer (combined
with chemotherapy), or as monotherapy in recurrent platinum
sensitive ovarian cancer, respectively. These results are expected
in 2019 and 2021.
Although these data might seem promising, many of the
clinical trials are ongoing and progress in the development of
these highly specific immunotherapeutic approaches to ovarian
cancer treatment is slow and a crucial clinical break-through is
still missing.
Sepsis induces a hyperactive immune system in response to
invading pathogens (28). Immune cells are activated by the
recognition of pathogen-associated molecular patterns (PAMPs)
that are present on microorganisms (29). This group of various
pathogens, which among others include lipopolysaccharides
Frontiers in Oncology | www.frontiersin.org 4 November 2018 | Volume 8 | Article 562
Roelofsen et al. Ovarian Carcinoma Regression After Sepsis
(LPS), a component of bacterial cell walls, interact with Toll-
like receptors (TLRs) on various immune cells (T lymphocytes,
DCs and neutrophils). Binding of the TLRs by PAMPs induces
activation of dendritic cells and cytotoxic T cells, leading to
a highly improved proinflammatory response that is able to
clear the invading pathogens. Sepsis not only stimulates the
adaptive immune response but it also activates innate immune
cells such as, granulocytes and macrophages. We detected a
shift in the CD8+ effector T cells/TReg ratio and M1/M2 ratio
when comparing the immune cell infiltrate before and after
sepsis. These results indicate that sepsis is able to overrule the
immunosuppressive tumor microenvironment, inducing a long-
lasting anti-tumor immune response that is still detectable 6
months after the sepsis. Non-specific activation (e.g., natural
or induced acute infection) of the innate immune system may
critically support the initiation of a functional specific immune
response against cancer.
The hyperactive immune response is accompanied by fever. A
febrile state enhances the cytokine secretion of immune cells with
an increase in proinflammatory cytokines. Furthermore, cancer
cells are more fragile and vulnerable to heat with apoptosis taking
place at lower temperatures compared to normal cells. Necrotic
or heat-stressed cancer cells can function as antigens or PAMPs
and thereby generate an immune-stimulating environment (30).
Recently, in patients with metastatic melanoma treated with
immunotherapy, fever of 39.5◦C or above was an independent
factor for improved survival and objective tumor response (31).
The use of bacteria, fungi, or components thereof might be a
promising path for non-specific immunotherapy against tumors
and might be a helpful adjuvant for specific immunotherapy.
The choice of pathogen or PAMP is essential in this scenario.
For example, activation of TLR-4 by LPS or its derivates
drives macrophage polarization toward anM1 pro-inflammatory
phenotype (32). Hence, TLR-4 agonists could be used to
target tumor-associated macrophages that counteract anti-tumor
immunity. However, since in vitro studies have shown that
TLR-4 on ovarian cancer cells promotes cell proliferation and
survival, more research is needed to investigate the use of TLR-
4 agonists (33, 34). The severity of the hyperactive immune
response is amongst others determined by pathogen-load and
virulence factor. If the activation of the immune system is
too strong, organ failure and death may occur. On the other
hand, if activation of the immune system is not strong enough,
the immunosuppressive tumor microenvironment may not be
overcome (35, 36). In addition to modern antigen-specific
antibody- and vaccine-based immunologic cancer therapies,
non-specific immunotherapies might serve as an ideal tool.
More insight in the interaction between ovarian cancer and
the immune system is needed to develop effective anti-
tumor immunotherapy. We believe that non-specific activation
of a broad immune response could tilt the balance from
an immune suppressive to an immune active environment.
This could have an impact on ovarian cancer treatment.
Can we boost the immune system using bacterial or fungal
components to evoke a potent and long-lasting anti-tumor
immune response?
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